A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma

Oncology

Volumn 78, Issue 3-4, 2010, Pages 210-212

  Balsom, Stephanie M ^e   Li, Xiaobai ^a,e   Trolli, Elizabeth ^b   Rose, Jeffrey ^b   Bloomston, Mark ^c,e   Patel, Tushar ^d,e   Bekaii Saab, Tanios S ^b,e,f  

^a Center for Biostatistics   (United States)

^b Division of Hematology and Oncology   (United States)

^c Division of Surgical Oncology   (United States)

^d Division of Hepatology   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Sorafenib

Indexed keywords

ERLOTINIB; LAPATINIB; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77951236058     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313701     Document Type: Article

References (11)

1. Garcia M, Jemal A, Ward EM, et al: Global Cancer Facts & Figures 2007. Atlanta, American Cancer Society, 2007.
2. El-Serag HB, Rudolph KL: Gastroenterology 2007; 132: 2557-2576.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
4. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
5. Bruix J: Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259-262.
6. Llovet JM, di Bisceglie AM, Bruix J: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
7. Llovet JM, Ricci s, Massaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular cancer. N Engl J Med 2008; 359: 420-422.
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States; National Cancer Institute of Canada: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
10. Ghassan AK, Schwartz L, Ricci S, Amadori D, Santoro A, Fieger A, De Greve J, Douillard J, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
11. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M: A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15: 5895-5901.